ATE248166T1 - 7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten - Google Patents

7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten

Info

Publication number
ATE248166T1
ATE248166T1 AT00935831T AT00935831T ATE248166T1 AT E248166 T1 ATE248166 T1 AT E248166T1 AT 00935831 T AT00935831 T AT 00935831T AT 00935831 T AT00935831 T AT 00935831T AT E248166 T1 ATE248166 T1 AT E248166T1
Authority
AT
Austria
Prior art keywords
heptanes
azabicyclo
oxo
receptor antagonists
muscarine receptor
Prior art date
Application number
AT00935831T
Other languages
English (en)
Inventor
Charles Howard Mitch
Steven James Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE248166T1 publication Critical patent/ATE248166T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00935831T 1999-06-04 2000-05-26 7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten ATE248166T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13777099P 1999-06-04 1999-06-04
PCT/US2000/009825 WO2000075140A1 (en) 1999-06-04 2000-05-26 7-oxo-2-azabicyclo[2.2.1]heptanes as selective muscarinic receptor antagonist

Publications (1)

Publication Number Publication Date
ATE248166T1 true ATE248166T1 (de) 2003-09-15

Family

ID=22478979

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935831T ATE248166T1 (de) 1999-06-04 2000-05-26 7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten

Country Status (7)

Country Link
US (1) US6559171B1 (de)
EP (1) EP1189902B1 (de)
AT (1) ATE248166T1 (de)
AU (1) AU5123200A (de)
DE (1) DE60004835T2 (de)
ES (1) ES2206244T3 (de)
WO (1) WO2000075140A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311201D0 (en) * 2003-05-15 2003-06-18 Merck Sharp & Dohme Therapeutic agents
WO2007110782A1 (en) * 2005-12-30 2007-10-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405853A (en) 1987-09-10 1995-04-11 Merck Sharpe & Dohme Ltd. Thiadiazoles useful in the treatment of senile dementia
EP0459568A3 (en) 1990-05-31 1992-09-30 Merck Sharp & Dohme Ltd. Substituted oxadiazoles and thiadiazoles for use in the treatment of glaucoma and novel compounds having such use
US5672709A (en) 1994-10-24 1997-09-30 Eli Lilly And Company Heterocyclic compounds and their preparation and use
AU1141497A (en) 1995-11-29 1997-06-19 Eli Lilly And Company Heterocyclic compounds and their use
US5889019A (en) 1995-11-29 1999-03-30 Eli Lilly And Company Heterocyclic compounds and their use
US5808087A (en) 1995-11-29 1998-09-15 Mitsui Chemicals, Inc. Sulfonium salts of pyrrolylbenzimidazoles
AU1128297A (en) 1995-12-06 1997-06-27 Eli Lilly And Company Composition for treating pain
CZ174698A3 (cs) 1995-12-07 1998-10-14 Eli Lilly And Company Léčivo pro léčbu bolesti
CA2239732A1 (en) 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain
JP2000509042A (ja) 1996-04-23 2000-07-18 イーライ・リリー・アンド・カンパニー ヘテロサイクリック化合物群
US5834458A (en) 1996-10-09 1998-11-10 Eli Lilly And Company Heterocyclic compounds and their use
WO1998046227A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain

Also Published As

Publication number Publication date
AU5123200A (en) 2000-12-28
ES2206244T3 (es) 2004-05-16
US6559171B1 (en) 2003-05-06
DE60004835D1 (de) 2003-10-02
DE60004835T2 (de) 2004-06-09
WO2000075140A1 (en) 2000-12-14
EP1189902B1 (de) 2003-08-27
EP1189902A1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
DE60222698D1 (de) Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5
MX2011002705A (es) Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
NZ595571A (en) Pyrazole compounds and uses thereof
MX2009012608A (es) Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso.
ATE423769T1 (de) Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
TW200609231A (en) Mglur1 antagonists as therapeutic agents
TW200634016A (en) Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors
ATE294774T1 (de) Aminoadamantan-derivate als therapeutische mittel
BR9609019A (pt) Compostos ativos em um novo local sobre canais de cálcio operados por receptor úteis no tratamento de desordens e doenças neurológicas
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
EA200300854A1 (ru) Применение обратных агонистов гамка в комбинации с частичными агонистами никотиновых рецепторов, эстрогеном, избирательными модуляторами эстрогена или витамином е для лечения познавательных расстройств
BR0206495A (pt) Tratamento de distúrbios de cns empregando antagonistas de oxidase de d-aminoácido e oxidase de d-aspartato
MX2012010657A (es) Compuestos de espiro amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso medico.
ATE339968T1 (de) Verwendung von mglur5 antagonists zur herstellung von medikamenten zur behandlung von empfindlichen x syndrome, autismus und geistiger zurückgebliebenheit
ATE419236T1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan- derivate als muscarinische rezeptorantagonisten
ATE401072T1 (de) 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem
MY124786A (en) Bis-arylsulfones
WO2007070393A3 (en) Mglur1 anatgonists as therapeutic agents
BR9803385A (pt) AtropisÈmeros de 2,3-dissubstituìdo-(5,6)-heteroaril condensado-pirimidin-4-onas.
ATE248166T1 (de) 7-oxo-2-azabicyclo(2.2.1)heptane als selektive muskarin-rezeptor antagonisten
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties